Carlos Barba

Dr. Carlos Barba


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
LGLinda P. Guamán
Linda P. Guamán
CBCarlos Barba
Carlos Barba
FZFuzhong Zhang
Fuzhong Zhang
Edmar R Oliveira-FilhoEdmar R Oliveira-Filho
Edmar R Oliveira-Filho
JGJosé Gregório Cabrera Gomez
José Gregório Cabrera Gomez
LSLuiziana Ferreira Da Silva
Luiziana Ferreira Da Silva
Despite its ability to grow and produce high-value molecules using renewable carbon sources, two main factors must be improved to use Burkholderia sacchari as a chassis for bioproduction at an industrial scale: first, the lack of molecular tools to engineer this organism and second, the inherently slow growth rate and poly-3-hydroxybutyrate [P(3HB)] production using xylose. In this work, we have addressed both factors. First, we adapted a set of BglBrick plasmids and showed tunable expression in B. sacchari. Finally, we assessed growth rate and P(3HB) production through overexpression of xylose transporters, catabolic or regulatory genes. Overexpression of xylR significantly improved growth rate (55.5% improvement), polymer yield (77.27% improvement), and resulted in 71% of cell dry weight as P(3HB). These values are unprecedented for P(3HB) accumulation using xylose as a sole carbon source and highlight the importance of precise expression control for improving utilization of hemicellulosic sugars in B. sacchari.

26 October 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
LGLinda P. Guaman-Bautista
Linda P. Guaman-Bautista
EMErick Moreta
Erick Moreta
COClaudia Oña-Arias
Claudia Oña-Arias
MTMarbel Torres
Marbel Torres
Nikolaos KyriakidisNikolaos Kyriakidis
Nikolaos Kyriakidis
CBCarlos Barba
Carlos Barba
The COVID-19 pandemic has had an enormous impact on economies and health systems globally, therefore a top priority is the development of increasingly better diagnostic and surveillance alternatives to slow down the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In order to establish massive testing and contact tracing policies, it is crucial to have a clear view of the diagnostic options available and their principal advantages and drawbacks. Although classical molecular methods such as RT-qPCR are broadly used, diagnostic alternatives based on technologies such as LAMP, antigen, serological testing, or the application of novel technologies such as CRISPR-Cas for diagnostics, are also discussed. The present review also discusses the most important automation strategies employed to increase testing capability. Several serological-based diagnostic kits are presented, as well as novel nanotechnology-based diagnostic methods. In summary, this review provides a clear diagnostic landscape of the most relevant tools to track COVID-19.